The development of drug delivery systems in experimental therapy usually requires in vitro release models, that should posses specific characteristics including: low cost, simple procedure, high reproducibility and very importantly resemble as strictly as possible the in vivo behaviour. In this respect, the paper describes the effects of the use of different experimental procedures on the drug release profiles from controlled delivery formulations based on nano and micro systems. As examples of micro and nanosystems, microparticles constituted of poly-lactide-co-glycolide (PEM) or gelatine (GEM) and nanostructured lipid carriers (NLC) or cubosomes (CBS) were selected, respectively. All the analysed formulations contained bromocriptine (BC) that represents a poorly water-soluble drug. The influence of the experimental release method and of release media has been investigated using different experimental set-up including direct and reverse dialysis, flow-through cell, USP XXII paddle and Franz cell methods.
INTRODUCTION
Advanced drug delivery formulations based on micro and nano systems have been widely proposed as carriers for small molecules and biologically active peptides and proteins [1] . These formulations have been named in different ways, due to their functional properties as well as to commercial reasons; names include: sustained release dosage forms, long acting, gradual release, prolonged release, slow release and controlled release. The concept of controlled drug release has emerged from the need for effective management of diseases [2] . Innovative formulations offer indeed many advantages over classical methods of drug delivery, including reduced frequency of administration, enhanced drug stability and patient compliance, reduced total dosage and decreased systemic side effects. Moreover, advanced drug delivery formulations allow optimized drug absorption, the release of the drug at particular body sites, continuous treatment in the nocturnal phase and reduced need for follow-up care.
Types of sustained release formulations include, among many others, solid polymeric particles (both of nano or micro dimensions) [3] [4] and lipid based formulations [5] such as microemulsions, solid lipid nanoparticles (SLN) and vesicular carries (liposomes, niosomes, ethosomes and cubosomes).
With respect to polymeric particles, a large number of materials and techniques with specific advantages have been proposed for their manufacturing [6] . Polymers are indeed preferred for the production of particulate systems; they are characterized by a large degree of variables that allow a fine drug release tuning and other functional properties. In addition, many drug delivery systems take advantages form polymer characteristics to stabilize the encapsulated molecules, during production and sterilization, to obtain desired release profiles and/or to achieve locally controlled delivery [7] [8] [9] .
Two classic examples of natural and synthetic polymers are respectively represented by gelatin and biodegradable poly (esters). Gelatin possess many features required for carrier system matrix in human use. It is indeed chemically and biochemically well characterized, biocompatible and commercially available in pyrogen-free form. In addition gelatin is non-toxic, non-immunogenic and can be eliminated from the body by normal routes [10] . All these characteristics have recommended its use for a large number of biomedical applications. Poly (esters) based on poly (lactic acid) (PLA), poly-(glycolic acid) (PGA), and their copolymers, poly (lactic acid-co-glycolic acid) (PLGA), are some of the best defined synthetic polymers with regard to design and performance in drug release by a controlled manner [11] . The polymers are derived from monomers that are natural metabolites of the body; thus degradation of these materials yields the corresponding hydroxy acid, making them safe for in vivo use.
Some lipids have a special amphiphilic character and when placed in water, they form various structures depending on their specific properties. Many lipids form micelles, others organize themself as lipid bilayers with the hydrophobic tails lined up against one another and the hydrophilic head-group facing the water on both sides. These unique features make lipids most suitable to be used as excipients for advanced drug delivery formulations, since it is increasingly apparent that formulations based on natural and/or synthetic lipids represent a viable means for enhancing the drug bioavailability of poorly water-soluble, highly lipophilic drugs [12] .
Irrespective of the chemical composition of the advanced drug delivery formulation, it should be considered that the therapeutic efficacy of the included drug is related to its release at the target site. The analysis of both amount and mechanism(s) of drug release, after administration, represents a major step for the development of nano-and microsystems. Usually these formulations release drug over long periods of time, therefore evaluation of release from microparticles requires long-term studies, in vivo (in animal recipients) or in vitro using physiologic conditions. In vitro release studies are generally preferred over the in vivo ones since are less laborious, time consuming and expensive. Even if in vitro experiments are not strictly predictive of the in vivo performances of the drug delivery systems, they give information about drug availability, formulation factors and manufacturing methods that could influence drug efficacy, batch to batch variability and substantiation of label claim of the product.
In spite of many practical approaches proposed for the determination of in vitro drug release kinetics and mechanism(s) from nano and micro systems, a few publications report about the reliability and reproducibility of the in vitro experimental models. Moreover, only few examples are present in the literature showing a comparative analysis of the release profile of a unique drug from various delivery systems, differing from size, composition and preparation procedures [13] .
To answer this point, in this paper we comparatively studied the in vitro release profile from micro and nano delivery systems of a model drug: the semi-synthetic ergot alkaloid bromocriptine (BC) (2-bromo--ergocryptine). BC is a dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome and type 2 diabetes [14] .
The analysed drug was previously entrapped in four different advanced delivery formulations: (a) microparticles constituted of a biodegradable synthetic polymer, namely poly-lactide-co-glycolide microparticles (PEM), (b) microspheres constituted of a natural polymer, namely gelatin microspheres (GEM), (c) nanostructured lipid carriers constituted of a lipid matrix with a mix of solid and liquid phases (NLC) [15] and (d) a liquid crystalline phase dispersed in water, mainly composed of cubosomes (CBS).
In particular, the latter delivery systems are respectively constituted by nanoparticles composed of a solid lipid matrix with a certain content of a liquid lipid phase (NLC) and by supramolecular aggregates of monoolein (mainly constituted of CBS and hexosomes often in coexistence with vesicles), dispersed in water and stabilized by the addition of block copolymers.
The in vitro release kinetics of BC was determined using different experimental models, namely: (a) direct and (b) reverse dialysis, (c) flow-through cell, (d) USP XXII paddle and (e) Franz cell methods. The comparison, in terms of results and reproducibility, between the different in vitro tests used to determine bromocriptine releases were analysed. In addition, in the case of microsystems, the mathematical analysis of the obtained BC release profiles was performed by semiempirical equation models.
Finally, the similarity or discrepancy between drug release profiles obtained with different in vitro models was briefly discussed.
MATERIALS & METHODS

Chemicals
Bromocriptine mesylate and Poly(D,L-lactide-coglycolide) (lactide:glycolide (50:50), mol wt 30,000-60,000) were from Sigma Chemical Co. (USA); the 250 bloom gelatin, glyceryl tripalmitate (GTP) and tristearate (GTS) were from Fluka Chemical, Co. (Buchs, Switzerland); glyceryl monostearate (GMS) and Compritol 888 ATO (a mixture of approximately 15% mono-, 50% di-and 35% triglycerides of behenic acid) were from Gattefossé (Saint-Priest Cedex, France) and glyceryl monooleate (GMO) was a gift from Danisco Cultor (Grindsted, Denmark); Miglyol 812, caprylic/capric triglycerides (tricaprin) was purchased from Eigenmann & Veronelli (Rho, Milano, Italy); polyvinyl alcohol Celvol205 (PVA) was from Celanese chemicals Europe GmbH (Kronberg, Germany): Poloxamer 407 and 188 were from BASF (Ludwigshafen, Germany). Carbopol 934P was from BFGoodrich (Cleveland, OH, USA).
Preparation of PEM
Microparticles were prepared by in-liquid drying process as elsewhere reported [16] . Briefly, 500 mg of polymer were dissolved in 15 mL of CH 2 Cl 2 . To this solution, 10 mg of BC were added and the mixture was emulsified into 200 mL of an aqueous phase containing 1 % (w/v) of 88 % hydrolysed PVA, as dispersing agent. The obtained emulsion was maintained under continuous stirring by a four-blade turbine impeller at 300 r.p.m. At different time intervals, samples were withdrawn and observed microscopically up to the complete evaporation of the organic solvent, usually occurring in 3-5 h.
Preparation of GEM
A gelatin solution (750 mg in 7 ml of water), pre-heated at 80°C, was added to 40 gr of isostearyl-isostearate warmed up at the same temperature [10] . The biphasic system, plus 0.1% (w/w) Tween 85, was stirred under turbulent flow conditions to form a w/o emulsion, using a mechanical stirrer (model IKA RW 20 DZM). After 5 minutes of continuous stirring, the emulsion was rapidly cooled at 5°C and then 50 ml of acetone were added in order to dehydrate and flocculate the coacervated particles. Gelatin microspheres were then isolated by filtering the suspension through a syntered glass filter. The incorporation of BC into gelatin microspheres was performed by placing 50 mg of microspheres in 1.2 ml of an ethanol/water mixture (95:5, v/v) containing 100 mg of BC and left to incubate for 3 hours. The microspheres were then filtered through a syntered glass filter. The final removal of solvent was performed by air-drying.
Preparation of NLC
NLC were prepared as previously reported [17] . Briefly, a lipid mixture constituted of GTS/tricaprin (2:1, w/w) was melted at 75°C and then 5 mg of BC were dispersed therein (0.025% w/w with respect to the total dispersions, 0.5% w/w with respect to the lipid phase). The lipid phase was then emulsified into 19 mL of an external aqueous phase containing 2.5 % (w/v) of poloxamer 188, as dispersing agent. The obtained emulsion was subjected to ultrasonication (Microson TM, Ultrasonic cell Disruptor) at 6.75 kHz for 15 min and then cooled down to room temperature by placing it in a water bath at 22°C.
Preparation of CBS
CBS were produced as previously described by minor modifications [18] . Particularly in the present study 12.5 mg of BC (0.27% w/w with respect to the monoolein, 0.025% w/w with respect to the entire dispersion) were added to the molten monoolein/poloxamer mixture before emulsification in water. Afterwards the dispersion was subjected to homogenization (15,000 rev min-1, Ultra Turrax, Janke & Kunkel, Ika-Werk, Sardo, Italy) at 60°C for 1 min, then cooled and maintained at room temperature in glass vials. The dispersion was then filtered through mixed esters cellulose membrane (0.6 m pore size) to remove large aggregates.
Morphological and Dimensional Analysis of Micro and Nano Systems
The size and morphology of micro systems was evaluated by observation on optical and scanning electron microscopy (SEM). Microsphere size and size distribution were determined by photomicrograph analysis. The size and morphology of nano systems were respectively determined by Photon Correlation Spectroscopy (PCS) and CryoTransmission Electron Microscopy (Cryo-TEM). Briefly, submicron particle size analysis was performed using a Zetasizer 3000 PCS (Malvern Instr., Malvern, England) equipped with a 5 mW helium neon laser with a wavelength output of 633 nm. Glassware was cleaned of dust by washing with detergent and rinsing twice with water for injections. Measurements were made at 25°C at an angle of 90°. Data were interpreted using the "method of cumulants" [19] . For Cryo-TEM, the vitrified specimens were transferred to a Zeiss EM922 transmission electron microscope for imaging using a cryoholder (CT3500, Gatan). The temperature of the sample was kept below -175°C throughout the examination. Samples were examined with doses of about 1000-2000 e/nm 2 at 200 kV. Images were recorded digitally by a CCD camera (Ultrascan 1000, Gatan) using an image processing system (GMS 1.4 software, Gatan). A drop of dispersion prepared for TEM measurements was placed on a bare copper grid and plunged frozen in liquid ethane at approximately -173°C. The sample was transferred into a cryo electron microscope (CEM902a, Zeiss, D-Oberkochen, Philips CM120, Eindhoven, the Netherland) operated at 80 kV respectively 120 kV. Samples were viewed under low dose conditions at a constant temperature around -196/-173°C. Images were acquired by a Dage SIT low intensity TV camera system and processed by a Kontron IBAS image processing system in the case of the Zeiss CEM902A and a Tietz Fastscan CCD camera system for the Philips CM120.
Drug content of Micro and Nano Systems
The amount of BC per unit weight of microparticles was determined as follows. 20 mg of microparticles were suspended in 3 ml of methanol at room temperature under magnetical stirring. After exhaustive extraction of BC, 20 l samples were analysed for BC content by reverse phase HPLC. In the case of nano systems, after production, the filtered dispersions were diluted with methanol (1:4 and 1:9, v/v for NLC and for CBS, respectively) and stirred for 3 h in order to completely extract BC. Thereafter, samples were passed trough a 0.45 Mm pore size filter and analysed by high performance liquid chromatography (HPLC) for BC content, as detailed below. For stability studies, the amount of BC detected by HPLC after filtration was taken as reference of the total amount of drug.
Determination of BC Release Kinetic
The in vitro release kinetics were determined by alternative approaches under different experimental conditions, namely dialysis, reverse dialysis, flow-through cell, USP XXII paddle and Franz cell methods. 6 runs were performed for each method. Dialysis method (for microsystems): typically 50 mg of microparticles were poured into a dialysis tube (molecular weight cut off 10,000-12,000; MediCell International, England), then placed into 100 ml of 50 mM citrate buffer, pH 3.5 and shaken in a horizontal shaker. Afterwards, samples were withdrawn at regular time intervals from the receiving buffer. The amount of released drug was determined by reverse phase HPLC. Dialysis method (for nanosystems): 5 ml of CBS or NLC were placed into a dialysis tube dipped into 100 ml of receiving phase, alternatively constituted of pure citrate buffer (50 mM, pH 3.5) or in mixture with ethanol or methanol and shaken horizontally (MS1, Minishaker, IKA, Germany) at 175 rpm and 37°C. At regular time intervals, 400 Ml samples of receiving buffer were withdrawn and refilled again with fresh medium. Reverse dialysis method: 5 ml of CBS were directly placed into 200 ml of a stirred solution, constituted of citrate buffer (50 mM, pH 3.5) and methanol (50:50 v/v) in which 10 dialysis sacs containing 1 ml of the same solution were previously immersed. The sacs were previously equilibrated with the solution for 30 min. At regular time intervals one dialysis bag was withdrawn and replaced with an equal volume of solution. The dialysis bag content was assayed by HPLC for BC concentration. Flow-through cell method: 20 mg of dry microparticles were placed into a 45x9 mm plexiglass column filled with 3 ml of 50 mM citrate buffer, pH 3.5. At the bottom of the column a polyethylene filter was set in order to prevent microparticle leakage; both ends were then fitted with Teflon tubes. Care was taken to ensure the quantitative transfer of microparticles to the column. Citrate buffer was pumped through the column at a flow rate of 0.12 ml/min by a peri-staltic pump. Fractions were collected and analyzed for BC content by reverse phase HPLC. USP XXII paddle method: the procedure was based on the use of an apparatus consisted of an approximately 25.4 34.92 mm stainless steel, 40-mesh paddle rotating at a constant speed of 100 rpm. The paddle was positioned inside a glass vessel placed in a water bath. 200 ml of a poloxamer 188 solution (0.1% w/v) in phosphate buffer (0.1 M, pH 7.4) was placed in the vessel and stirred by the paddle. 8 ml of NLC was poured in the vessel. At regular time intervals, 1 ml samples were withdrawn from the vessel and refilled again with fresh medium. 200 l of samples were filtered through nylon filters (Steriflip, pore size 0.1 m pore size, Millipore, MA) and analysed by HPLC. The filters were validated with regard to drug adsorption. Franz type glass diffusion cell: the cell was assembled with a nylon membrane (GNWP, 0.2 m pore size, Millipore, MA). The cell body was filled with a receptor phase constituted of 100 mM phosphate buffer, pH 7.4. 1 g of CBS was placed into the donor cell compartment, the membrane was previously moistened with the receptor phase. Samples of receptor phase were withdrawn after predetermined time intervals and the BC concentration was measured by using a HPLC analytical procedure. Each removed sample was replaced with an equal volume of simple receptor phase. Samples were then diluted with methanol in a 1:1 v/v ratio. The amount of drug released was determined by HPLC (using the analytical method described below). All the release studies were performed at a fixed temperature of 37°C ± 0.1°C. Measurements were conducted three times per sample; mean values and standard deviations were also calculated.
HPLC-Chromatography
The HPLC determination of BC was conducted using a two-plunger alternative pump (Jasco, Japan), an UV-detector operating at 305 nm and a 7125 Rheodyne injection valve with a 50 Jl loop. Samples were loaded on a stainless steel C-18 reverse-phase column (15 0.46 cm) packed with 5 Jm particles (Hypersil BDS, Alltech, USA). Elution was performed at room temperature with a mobile phase constituted of ammonium formate (pH 3, 0.1M) and acetonitrile 55:45 v/v at a flow rate of 0.8 ml/min. The retention time of BC was 5.8 min. The BC content of samples from release experiments was obtained from a BC calibration curve constructed from standard solutions.
BC Release Data Analysis
The experimental release data obtained with both methods were then fitted to the following semiempirical equations respectively describing Fickian diffusional and dissolutive release mechanisms from microspheres. 
RESULTS AND DISCUSSION
Release Profiles from Micro and Nano Systems: General Considerations
The development of delivery systems for therapeutical applications usually requires the determination of in vitro release profiles by experimental methods possessing specific characteristics including: low cost, simple procedure, high reproducibility and very importantly they should resemble, as strictly as possible, the in vivo behaviour.
In vitro studies provide indeed information on the physicochemical structure of the excipients used in the formulations, including solid particle porosity, interactions between actives and excipients and excipient effects on the rate and mechanism of drug release. Finally, the experimental release data can be mathematically modeled in order to have indications about the different drug release modalities, such as drug desorption from particle surface, diffusion through particle matrix or matrix dissolution.
For the development of an appropriate in vitro release method, many aspects should be considered. For instance, the selection of the "receiving" medium represents an important step, both in term of composition and temperature, in consideration of drug solubility, stability and maintenance of sink conditions. Regarding this latest aspect, it is noteworthy to consider that sink conditions may not occur at some in vivo administration sites, especially in the case of subcutaneous or intramuscular injections.
In principle, in vitro release methods could also provide insights about the influence of changes in the manufacturing procedure on the formulation. This feature is particularly focused on a quality-control point of view and could be usefully employed in the design and development of drug formulations based on nano and microsystems.
Preparation of Microsystems
In order to assess the robustness, reproducibility and reliability of in vitro tests for the determination of drug release from microparticles, two different delivery systems were considered, namely: PEM and GEM.
On the one hand, PEM were prepared by an in-liquid drying process involving the evaporation of methylene chloride from an O/W emulsion. The obtained microparticles show a smooth surface, no aggregation phenomena and regular spherical shape (see Fig. 1 A-B) .
On the other one, GEM were obtained by a thermal coacervation technique. Also in this case the employed experimental set-up resulted in the production of microparticles characterized by a high degree of homogeneity, smooth surface with only a few small pores (Fig. 2 A-B) .
The design and the choice of the experimental set-up, for both PEM and GEM, were accomplished having a dimensional target adequate to subcutaneous or intramuscular administration procedures. Microparticles with an average diameter comprised between 30.00 and 50.00 m appear indeed optimally suitable for these administration procedures since (a) they assure sufficiently long release periods and (b) avoid possible syringe needle blockage. As summarized in Table 1 , the adopted preparation procedures resulted in the formation of microparticles perfectly fitting the dimensional constrains initially set, with a mean diameter of 48.00±12.00 and 34.30±14.00 m, for PEM and GEM, respectively.
Preparation of Nanosystems
To investigate the influence of the experimental method on the drug release profile from nanosystem, NLC and CBS were produced. Both nanosystems were obtained by the emulsification of a lipid phase in water, followed by a size reduction method, namely ultrasonication for NLC and homogenization for CBS (see Table 1 ) [17] . Notably, the two nanosystems have different morphological characteristics, as proved by the cryo-transmission electron (Cryo-TEM) microphotographs reported in Figs. (3 and 4) . The microscopic analyses allowed shedding light on the structure of both nanosystems, showing that NLC are solid systems while CBS are supramolecular aggragates characterized by the coexistence of cubosomes and vesicles. In particular, Fig.  (3A) shows the typical structure of NCL that contains a mixture of deformed hexagonal, elongated and circular plateletlike particles, (most likely viewed from the top). The cryo-TEM analysis reveals that NLC samples contain also an appreciable number of "needle"-like structures, probably due to the presence of tricaprin crystals, together with hemielliptical particles, showing inner striations that could correspond to edge-on view of NLC particles. Analogously, Fig. (4) reports the cryo-TEM images of BC-containing CBS. The microphotograph reported in Fig.  (4A) clearly indicates that CBS are constituted of a mixture of well-shaped particles, with a homogeneous, cubic inner structure, vesicles and particles having vesicular structures attached on their surface. At higher magnification, the cryo-TEM image reported in Fig. (4B) shows the typical cubic ordered structure of cubosomes. 
Analysis of BC Release Kinetic from Micro and Nano Systems
Microsystems. To adequately characterize the release from micro and nano particles, it is mandatory to obtain drug release data, relating to the amount of the delivered drug as a function of the time. To this goal different methods have been proposed including simple approaches in which the dried form of the delivery system is directly dispersed into a small volume of release buffer contained in vials, beakers, round bottom flasks or bottles. At different length of time, samples are withdrawn followed by procedures aimed to separate the liquid release media from the solid particles (e.g. filtration or centrifugation).
As alternative, membrane (dialysis) methods have also been proposed to separate the particles from the release buffer. Continuous flow-through methods represent another alternative, based on the use of a liquid buffer flowing through an apparatus (usually a chromatographic column), in which the micro and nano particles are previously loaded. This latest method has been used to resemble in vivo conditions, especially those occurring after intravenous injections of nanoparticle based delivery systems.
Generally, the release methods posses both specific advantages as well as some disadvantages. For instance, the dialysis protocol has been criticized for the absence of sink conditions and the occurrence of aggregation phenomena (of the nano and microparticulate elements), due to the limited agitation within the dialysis space. Conversely, continuous flow-through methods can suffer from high interlaboratory variability, depending by the hardware (i.e. pumps and columns) and experimental set-up (i.e. buffers and flow rates) employed.
In addition, It should be considered that in vitro release tests described in different Pharmacopoeias are generally designed for oral and transdermal products and they are poorly applicable to parenteral products (administered subcutaneously or intramuscularly), especially those based on nanoparticles.
In the current investigation, in order to evaluate the effect of the experimental method on BC release profiles, 5 different in vitro release methods were evaluated, namely: (a) dialysis, (b) reverse dialysis, (c) flow through cell, (d) USP XXII paddle and (e) Franz cell methods (see Table 2 ). In addition 4 different formulations, all containing BC, were produced and analyzed, namely: PEM, GEM, NLC and CBS.
It should be pointed out that the dialysis method was selected because it reproduces the subcutaneous or intramuscular administration routes, in which the solid particles are in non-sink conditions, presumably surrounded by a stagnant layer causing a slow diffusion of the drug. The flow through cell method was chosen since it mimics more strictly the in vivo condition occurring after intravenous injection, representing the typical way of administration for nano systems.
In spite of many criticisms issued for the paddle method (in reason of highly non-uniform hydrodynamics that results in fluctuations in the release rate measurements), it was considered since it is a standard Pharmacopeia method, even if it is more appropriate for drug dissolution tests from tablets. Finally, the Franz cell method was chosen as a well established methodology to evaluate the in vitro drug release from topical formulations or the penetration of drug across the skin.
In Fig. (1 C-D) are reported the BC release profiles from PEM‚ determined by using dialysis (Fig. 1C) or flow through cell (Fig. 1D) methods.
As clearly appreciable, the obtained profiles are different from each other. In the case of release profile determined by dialysis, the plateau is reached in about 60 hours (8.2 mg of released BC/100 mg of microspheres) as appreciable from the entire release profile reported in the inset of panel C. In the case of release determined by column, the plateau is reached in a much shorter time of about 10 hours (as reported in the inset of panel D). In spite of the recorded differences, the shape of the profiles is substantially identical in both cases. From a practical point of view, the flow-through cell method appears more reproducible (average of the standard deviation of the experimental point values equal to 0.148) with respect to the dialysis one (SD average equal to 0.499). Moreover, the flow through cell method possesses the further advantage of offering the possibility to be equipped with a HPLC UV-VIS detector and/or a fraction collector allowing the automatic analysis of samples.
As further investigation, we determined whether or not the release data obtained by the above described experimental methods could lead to different interpretations of the drug release mechanism when analyzed by mathematical models.
In this respect, Fig. (1C) reports the plots of BC experimental release data (filled circles), obtained with the dialysis method and, for comparison, the theoretical release curves calculated according to the linear form of equations (1) (dashed line) and (2) (solid line), respectively mimicking dissolutive and diffusive models. In the same way, in Fig.  (1D) are shown the experimental and theoretical release profiles determined by the flow through cell method. For comparison, in Table 3 are reported the parameters K and c and the regression coefficients R, determined by linearization of the two sets of experimental data following equation (1) and (2) .
Similarly, in Fig. (2) is reported the release profile of BC from GEM performed by the dialysis method. In this case, the release profile of BC from GEM appears to be constituted of two different phases: an initial period (about the first 4 hours) characterized by a rapid release during which about 35% of the total entrapped drug is released and a second period characterized by a much slower rate, in which the BC release was approximately linear. Fig. (2C) reports both the experimental data (filled circles) and the theoretical release curves calculated according to the linear form of equations (1) (dashed line) and (2) (solid line). The comparative analysis of the release of BC from GEM and PEM indicates that the two profiles slightly differ in term of both released drug and curve shapes.
All together, the results relative to microsystems allow withdrawing some important considerations. The use of different experimental approaches to determine the release kinetics from disperse systems can give distinct results in term of drug availability. This point is particularly crucial, especially if we consider that information contained in the release curve are generally used for the determination of the therapeutic dose (bioavailable drug) and for quality control to ensure batch to batch uniformity. In term of mathematical treatment, the analysis of different sets of experimental data, leads to almost identical conclusions; in the case of PEM, the BC release appears to be more consistent with a kinetic of the diffusive type rather than of dissolutive one. This hypothesis is supported by the higher value of the regression coefficients found in the case of linearization with equation (2) .
Nanosystems. The method employed for the determination of drug release kinetics from nanosystems is a crucial point; in vitro methods have been often criticized for different reasons including: the difficult application to lipophilic drugs and the scarce predictivity with respect to the in vivo bioavailability [21, 22] .
Indeed slow drug release from nanoparticles is often claimed, but a slow appearance of drug in the release medium can be an artificial result of an inadequate experimental setup rather than a true property of the nanosystem [15] . Accordingly, in the present investigation, we employed different in vitro systems and receiving phases to analyze their effect on BC release from NLC and CBS (see Table 2 ).
The use of a receiving phase based on aqueous buffers (often claimed to be physiological) usually leads to a negligible release of BC, because of its poor solubility in media with a pH > pKa (5.87) [15] . In reason of this fundamental constrain, the determination of BC release was performed using a receiving phase characterized by a non-physiological pH and a relatively high proportion of organic solvents in mixture with water.
For instance, Fig. (3C) reports the BC release kinetics from NLC determined by dialysis method using different receiving phases (see Table 2 ). The use of citrate pH 3,5 buffer (circles) led to the slowest release (3 % of BC released after 10 hours), the addition of an organic solvent, citrate/methanol (80/20 %, v/v) caused an increase of BC release up to 12 % in the same period of time (diamonds); the faster release of BC was observed when the amount of organic solvent was further increased up to 50 % (citrate/ethanol, 50/50 %, v/v), resulting in a 60 % BC release in 10 hours.
In Fig. (3C) is also reported the release profile of BC from NLC, determined determined by USP XXII paddle method, using as receiving buffer a poloxamer solution in phosphate buffer (triangles). This in vitro method resulted in a BC release of 11% after 10 hours.
A further analysis of the effect of different release method was conducted on CBS (Fig. 4) . For instance, Fig.  (4C) reports the effect of the receiving phase on the BC release profiles determined by dialysis method. Notably, in the case of CBS, plain citrate buffer (circles) or mixture water/methanol (50/50 %, v/v) (diamonds), resulted in similar profiles, characterized by BC release, after 12 h, comprised in the range of 30-35 %. A remarkably higher BC release (58 % after 12 h) was observed when, as receiving phase, a mixture of citrate/ethanol (50/50 %, v/v) was employed. These results reflect the influence of the organic phase on the solubility of BC.
Furthermore, Fig. (4D) reports the BC release kinetics from CBS obtained by reverse dialysis and Franz cell methods. In the case of reverse dialysis, two receiving phases were tested, namely citrate/ethanol (50/50 %, v/v) (squares), or water/methanol (80/20 %, v/v) (diamonds) mixtures. In both cases BC was released from CBS more rapidly with respect to the other above reported experimental conditions, reaching a 60% of release reached within 4 h. The presence of ethanol promotes the release of BC because the solvent interacts with the CBS components [23] , presumably resulting in a final disorganization of the cubic structure and drug leakage. Lastly, we tested the Franz cell method using a dialysis membrane and 0.1 M phosphate buffer (pH 7.4) as receiving phase, that resulted in an almost negligible BC release within a period of 24 h (BC < 0.8%).
Very importantly our data indicate that the in vitro release of poorly water soluble drugs (as BC, used in our study) is more affected by the composition of the receiving phase (i.e. in term of presence of water miscible polar organic solvents) rather than by the experimental modality adopted for the in vitro determinations. This latest point opens an important topic of discussion about the use of "so called" physiological conditions (i.e. based on pure water phases at neutral pH) for in vitro experiments that in our opinion are not always resembling the milieu of specific administration routes, as in the case of intramuscular injections.
On the basis of these considerations, the use of accurate and reliable in vitro tests and more importantly the choice of an adequate receiving phase appear to be crucial for the determination of drug release profiles from micro and nano system dosage forms.
CONCLUSION
The current paper demonstrated the influence of different experimental set-up, designed to determine the in vitro release profiles from advanced drug delivery systems, on the mathematical modelling of experimental release curves.
We believe that the presented data represent an interesting topic in pharmaceutics; the development of drug dosage form requires indeed in vitro release tests able to evaluate the in vitro behaviour under different conditions (pH, agitation, dissolution medium), possibly resembling the in vivo drug bioavailability.
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